We are live on ! Find out more
MRKR icon

Marker Therapeutics
MRKR

47 hedge funds and large institutions have $5.24M invested in Marker Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

4% more funds holding

Funds holding: 45 → 47 (+2)

0.11% less ownership

Funds ownership: 2.45% → 2.34% (-0.11%)

31% less capital invested

Capital invested by funds: $7.56M → $5.24M (-$2.32M)

Holders
47
Holders Change
+2
Holders Change %
+4.44%
% of All Funds
0.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
10
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$58.4K
2
Osaic Holdings
Osaic Holdings
Arizona
+$9.58K
3
TSS
Two Sigma Securities
New York
+$6.46K
4
Jane Street
Jane Street
New York
+$4.27K
5
Renaissance Technologies
Renaissance Technologies
New York
+$4.04K

Top Sellers

Rank Fund Capital Flow
1
AAM
AR Asset Management
California
-$103K
2
BCM
Bridgeway Capital Management
Texas
-$92K
3
MAA
Matrix Asset Advisors
New York
-$51.8K
4
UBS Group
UBS Group
Switzerland
-$14.8K
5
Two Sigma Investments
Two Sigma Investments
New York
-$13.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$2.85M – – –
ACM
2
Aisling Capital Management
New York
$849K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$470K +$538 +156 +0.1%
LFCM
4
Long Focus Capital Management
Puerto Rico
$388K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$152K -$538 -156 -0.3%
MAA
6
Matrix Asset Advisors
New York
$67.5K -$51.8K -15,000 -38%
State Street
7
State Street
Massachusetts
$49.4K – – –
Creative Planning
8
Creative Planning
Kansas
$48.3K – – –
Millennium Management
9
Millennium Management
New York
$45K +$58.4K +16,932 New
Renaissance Technologies
10
Renaissance Technologies
New York
$43K +$4.04K +1,170 +8%
BlackRock
11
BlackRock
New York
$33.9K +$3.46K +1,003 +9%
IA
12
IFP Advisors
Florida
$30K +$407 +118 +51%
Northern Trust
13
Northern Trust
Illinois
$28.9K – – –
MLIC
14
Mandatum Life Insurance Company
Finland
$26K – – –
RJA
15
Raymond James & Associates
Florida
$25K – – –
WS
16
Wedbush Securities
California
$22K -$5.52K -1,600 -16%
Osaic Holdings
17
Osaic Holdings
Arizona
$20.6K +$9.58K +2,778 +60%
NRS
18
Neville Rodie & Shaw
New York
$16K – – –
PCA
19
Personal Capital Advisors
California
$6.84K – – –
WA
20
WealthTrust Axiom
Pennsylvania
$6.04K – – –
HighTower Advisors
21
HighTower Advisors
Illinois
$6K +$1.73K +500 +29%
Morgan Stanley
22
Morgan Stanley
New York
$5.08K +$3 +1 +0.1%
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
$5K – – –
TSS
24
Two Sigma Securities
New York
$4.98K +$6.46K +1,873 New
RAM
25
Riggs Asset Management
Pennsylvania
$4.92K – – –
1
2 3

MRKR Hedge Fund Activity: Q4 2022 in Review

47 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2022, worth a combined $5.24M — down 31% from $7.56M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new MRKR positions and 4 closed out — a net gain of 4 holders — while 10 added to existing stakes and 9 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $58.4K. The largest seller was AR Asset Management, exiting entirely with an estimated $103K sold.

  • 47 institutional investors held Marker Therapeutics (MRKR) as of Q4 2022, up from 45 in Q3 2022.
  • Funds reported $5.24M of Marker Therapeutics stock for Q4 2022, down 31% quarter-over-quarter.
  • 8 funds opened new Marker Therapeutics positions in Q4 2022 and 4 closed out, a net change of +4 holders.
  • The largest Marker Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $58.4K added.
  • The largest Marker Therapeutics seller in Q4 2022 was AR Asset Management, an estimated $103K sold.

Based on aggregated 13F filings for Q4 2022.